Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €16.35 EUR
Change Today -0.31 / -1.86%
Volume 293.3K
ALM On Other Exchanges
Symbol
Exchange
Frankfurt
OTC US
Continuous
As of 10:19 AM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

almirall sa (ALM) Snapshot

Open
€16.62
Previous Close
€16.66
Day High
€16.80
Day Low
€16.22
52 Week High
03/31/15 - €17.50
52 Week Low
07/28/14 - €10.61
Market Cap
2.8B
Average Volume 10 Days
322.0K
EPS TTM
€2.59
Shares Outstanding
173.0M
EX-Date
--
P/E TM
6.3x
Dividend
€0.20
Dividend Yield
--
Current Stock Chart for ALMIRALL SA (ALM)

Related News

No related news articles were found.

almirall sa (ALM) Related Businessweek News

No Related Businessweek News Found

almirall sa (ALM) Details

Almirall, S.A., a pharmaceutical company, researches, develops, manufactures, and markets proprietary and licensed medicines worldwide. The company offers its products for dermatological diseases comprising actinic keratosis, psoriasis, eczema, and skin infections; and gastrointestinal diseases, such as irritable bowel syndrome, as well as for pain. Its products include LAS100977, a potent bronchodilator, which is in phase IIa clinical trial for the treatment of asthma and chronic obstructive pulmonary disease (COPD); LAS190792, a dual long-acting muscarinic antagonist ß2 agonist that is in Phase I clinical for treating COPD; and LAS40464, an aclidinium bromide and formoterol for the treatment of COPD. The company also develops LAS41004, a compound that is in Phase II clinical trials for the treatment of psoriasis and/or atopic dermatitis; LAS41008, which is in Phase III clinical trial for treating psoriasis; and Sativex, an oromucosal spray is in Phase III clinical trial for the treatment of spasticity in patients with multiple sclerosis. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.

1,993 Employees
Last Reported Date: 02/23/15
Founded in 1943

almirall sa (ALM) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

almirall sa (ALM) Key Developments

Almirall Reduces R&D Capacity in Cost-Saving Move

Almirall has announced a restructuring to its research and development (R&D) department with the loss of 68 jobs. Almirall's main reasons for the cuts are reduction of costs and increased focus on its dermatology portfolio, which demands less staff. Almirall has clarified that its German facility will not be part of the staff restructuring.

Almirall Proposes Dividend

Almirall announced that the Board of Directors will propose to the general assembly a dividend of EUR 0.2 per share, which represents a disbursement of EUR 35 million.

Almirall, S.A. Reports Earnings Results for the Full Year Ended December 31, 2014; Provides Earnings Guidance for the Full Year of 2015

Almirall, S.A. reported earnings results for the full year ended December 31, 2014. For the year, the company reported total revenues of EUR 1,407.4 million compared to EUR 825.5 million a year ago. EBITDA was EUR 686.3 million compared to EUR 85.1 million a year ago. Net income was EUR 448.4 million compared to net loss of EUR 33.7 million a year ago. Normalized net income was EUR 43.5 million compared to EUR 31 million a year ago. The company provided earnings guidance for the full year of 2015. For the year, the company expects total revenues in the range of EUR 720 million to EUR 750 million and net sales in between EUR 650 and EUR 680 million. That together with a significant Opex reduction are expected to deliver an EBIT of approximately EUR 100 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALM:SM €16.35 EUR -0.31

ALM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
H Lundbeck A/S kr157.00 DKK +26.50
Ironwood Pharmaceuticals Inc $13.75 USD +0.26
Nektar Therapeutics $11.32 USD +0.15
Synergy Health PLC 2,228 GBp -2.00
Theravance Inc $15.88 USD -0.72
View Industry Companies
 

Industry Analysis

ALM

Industry Average

Valuation ALM Industry Range
Price/Earnings 6.1x
Price/Sales 3.3x
Price/Book 2.0x
Price/Cash Flow 5.2x
TEV/Sales 1.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALMIRALL SA, please visit www.almirall.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.